Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial - Scorecard - MDSpire

Evaluating the Efficacy of Combined Antithrombotic Treatment with Strong Antiplatelet Agents in Patients with Atrial Fibrillation and Acute Coronary Syndrome: A Randomized Controlled Study

Nature Medicine

Share

Clinical Scorecard: Evaluating the Efficacy of Combined Antithrombotic Treatment with Strong Antiplatelet Agents in Patients with Atrial Fibrillation and Acute Coronary Syndrome: A Randomized Controlled Study

At a Glance

Category	Detail
Condition	Atrial Fibrillation and Acute Coronary Syndrome
Key Mechanisms	Triple antithrombotic therapy (TAT) vs. dual antithrombotic therapy (DAT) with a focus on ischemic-event prevention and bleeding avoidance.
Target Population	Patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention.
Care Setting	Clinical trial setting across multiple medical centers.

Key Highlights

Triple antithrombotic therapy increases bleeding risk.
Dual antithrombotic therapy with DOAC and P2Y12 inhibitor may lower bleeding risk.
Potent P2Y12 inhibitors (ticagrelor, prasugrel) show better outcomes than clopidogrel.
The trial was stopped early due to safety concerns and lack of superiority.
CHA2DS2-VA and HAS-BLED scores were used to assess stroke and bleeding risk.

Guideline-Based Recommendations

Diagnosis

Use CHA2DS2-VA score to assess stroke risk in AF patients.
Use HAS-BLED score to assess bleeding risk in AF patients receiving OAC.

Management

Consider potent P2Y12 inhibitors with DOACs in high stent-thrombosis risk patients.

Monitoring & Follow-up

Monitor adherence to antithrombotic strategies and assess for bleeding events.

Risks

Increased risk of bleeding and ischemic events with certain antithrombotic combinations.

Patient & Prescribing Data

Patients aged 78 years on average, with a median CHA2DS2-VA score of 4 and HAS-BLED score of 3.

Potent P2Y12 inhibitors were administered to 96.2% of the experimental group.

Clinical Best Practices

Evaluate individual patient risk factors before antithrombotic therapy.
Consider switching from potent P2Y12 inhibitors to clopidogrel after the initial treatment phase.

Related Resources & Content

Study Source

Original Source(s)

Nature Medicine

Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial

by Konstantinos D. Rizas, Konstantinos Mourouzis, Dominik Rath, Christoph B. Olivier, Laura Elisa Villegas Sierra, Theofanis Korovesis, Amin Polzin, Amani Al Tawil, Reza Wakili, Lukas von Stuelpnagel, Katharina Mayer, Marion Janisch, Tanja Ulrich, Sarah Lang, Sebastian K. G. Maier, Florian Brattinger, Lorenz Bott-Flügel, Harilaos Bogossian, Konstantinos Iliodromitis, Luisa Freyer, Julius Steffen, Konstantin Stark, Elodie Eiffener, Lauren E. Sams, Tobias Petzold, Axel Linke, Felix M. Heidrich, Samuel Sossala, Saif Zako, Nikolaos Dagkonakis, Andreas Schäfer, Frank Edelmann, David M. Leistner, Mariya Maslarska, Fabian Knebel, Georg Nickenig, Blerim Luani, Tienush Rassaf, Hüseyin Ince, Ibrahim Akin, Micha T. Maeder, Meinrad Gawaz, Hans-Josef Feistritzer, Norbert Frey, Stefan Kääb, Riza Sahin, Matthias Pauschinger, Thomas Stiermaier, Ingo Eitel, Marc Kollum, Jan Sebastian Wolter, Michael Schreinlechner, Axel Bauer, Christoph Stellbrink, Ulf Landmesser, Paulus Kirchhof, Dirk Sibbing, Holger Thiele, Adnan Kastrati, Ulrich Mansmann, Steffen Massberg
August 29, 2026

Related Content

Frontiers In Cardiovascular Medicine

Precision approach for transradial access during PCI: a state-of-the-art review

Frontiers In Cardiovascular Medicine

Risk assessment of acute heart failure after endovascular therapy in acute ischemic stroke: a nomogram-based study

Frontiers In Medicine

Admission ECG-derived resting heart rate and in-hospital mortality after acute stroke: a multicenter retrospective cohort study